<!doctype html>
<html lang="en">
    <head>
        <meta charset="utf-8" />
        <title>
            Discovery
        </title>
        <meta name="viewport" content="width=device-width, initial-scale=1" />
        <link
            rel="icon"
            type="image/png"
            href="/images/faviconPIRSMSmall.png"
        />
        <!-- Google Fonts CDN -->
        <link rel="preconnect" href="https://fonts.googleapis.com" />
        <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
        <link
            href="https://fonts.googleapis.com/css2?family=Playfair+Display:wght@400;700&display=swap"
            rel="stylesheet"
        />
        <!-- Self host font -->
        <!-- <link rel="preload" href="/assets/fonts/playfair-display.woff2" as="font" type="font/woff2" crossorigin> -->
        <link
            href="/assets/css/style.css"
            rel="stylesheet"
        />

         
        <meta property="og:title" content="Discovery" />
        
        <meta property="og:type" content="website" />
        <meta property="og:url" content="" />
         
        <meta name="twitter:card" content="summary" />
        
        <meta name="twitter:site" content="" />
         
        <meta
            name="twitter:creator"
            content=""
        />
        
    </head>

    <body class="page page-solution">
        <div id="main-menu-mobile" class="main-menu-mobile">
  
  <ul>
    
    <li class="">
      <a href="/solutions/">Solutions</a>
    </li>
    
    <li class="">
      <a href="/team/">Team</a>
    </li>
    
    <li class="">
      <a href="/about/">About</a>
    </li>
    
    <li class="">
      <a href="/contact/">Contact</a>
    </li>
    
  </ul>
</div>

        <div id="wrapper" class="wrapper">
            <div class='header'>
  <div class="container">
    <div class="logo">
      <a href="/"><img width="180px" height="48px" alt="Digital PRISM – Therapeutic Intelligence" src="/images/logo/logo-wide.svg" /></a>
    </div>
    <div class="logo-mobile">
      <a href="/"><img width="32px" height="32px" alt="Digital PRISM – Therapeutic Intelligence" src="/images/logo/logo-mobile.svg" /></a>
    </div>
    <div id="main-menu" class="main-menu">
  
  <ul>
    
    <li class="">
      <a href="/solutions/">Solutions</a>
    </li>
    
    <li class="">
      <a href="/team/">Team</a>
    </li>
    
    <li class="">
      <a href="/about/">About</a>
    </li>
    
    <li class="">
      <a href="/contact/">Contact</a>
    </li>
    
  </ul>
</div>

    <button id="toggle-main-menu-mobile" class="hamburger hamburger--slider" type="button" aria-label="Mobile Menu">
  <span class="hamburger-box">
    <span class="hamburger-inner"></span>
  </span>
</button>
  </div>
</div>
 <div class="container pb-6 pt-6 pt-md-10 pb-md-10">
    <div class="row justify-content-start">
        <div class="col-12 col-md-8">
            <div class="solution solution-single">
                <h1 class="title">Discovery</h1>
                <div class="content"><p>Discovery of Digital Therapeutics (DTx) follows a structured and methodical process, much like traditional drug discovery.</p>

<h1 id="phases">Phases</h1>

<ul>
  <li>Target Identification,</li>
  <li>Hit Identification, and</li>
  <li>Lead Optimization.</li>
</ul>

<h1 id="risk-profiles">Risk profiles</h1>

<p><img src="/images/illustrations/risk-type.svg" alt="" /></p>

<h2 id="target-identification">Target Identification</h2>

<ul>
  <li><strong>Domains and Constructs:</strong> Organized into broad functional domains (e.g., Cognitive Systems, Negative/Positive Valence Systems).</li>
  <li><strong>Multi-Level Analysis:</strong> Examines genes, molecules, circuits, behavior, and self-reports to create a comprehensive view of DTx target and ‘undruggable’ opportunities.</li>
  <li><strong>Dimensional Approach:</strong> Views symptoms along a spectrum, allowing for variation across conditions and populations.</li>
  <li><strong>Cross-Diagnostic:</strong> Encourages research across different disorders, offering insights into shared mechanisms.</li>
</ul>

<!--This stage involves pinpointing the physiological or psychological mechanisms that a DTx could modulate to achieve therapeutic outcomes. It starts by identifying the relevant biological or behavioral targets that underlie the condition being addressed. For DTx, these targets may be cognitive, neurological, or behavioral pathways, depending on the therapeutic focus.-->

<h2 id="hit-identification">Hit Identification</h2>

<p>Once the target is identified, the process moves to screening potential digital interventions—these could be algorithms, behavioral models, or software-driven protocols that show the potential to interact with the identified targets effectively. The goal at this phase is to find “hits”—early-stage interventions that demonstrate initial promise in modulating the desired pathways or outcomes.</p>

<!--Once the target is identified, the process moves to screening potential digital interventions—these could be algorithms, behavioral models, or software-driven protocols that show the potential to interact with the identified targets effectively. The goal at this phase is to find "hits"—early-stage interventions that demonstrate initial promise in modulating the desired pathways or outcomes.-->

<h2 id="lead-optimization">Lead Optimization</h2>

<p>From the pool of hits, a lead candidate is selected. This candidate represents the most promising digital therapeutic intervention, one that not only targets the identified pathways but also offers potential clinical efficacy. During this stage, the intervention is refined, tested, and adjusted, both to improve its therapeutic effect and to mitigate any early-stage risks. The outcome is a well-defined digital therapeutic candidate ready for preclinical testing and further development.</p>

<!--From the pool of hits, a lead candidate is selected. This candidate represents the most promising digital therapeutic intervention, one that not only targets the identified pathways but also offers potential clinical efficacy. During this stage, the intervention is refined, tested, and adjusted, both to improve its therapeutic effect and to mitigate any early-stage risks. The outcome is a well-defined digital therapeutic candidate ready for preclinical testing and further development.-->

<p>Throughout all phases of the discovery process, we follow an evolutionary approach with a Target Product Profile guided by the V-model.</p>

<p>At the conclusion of the discovery phase, we have a lead candidate with an initial risk profile.</p>
</div>
            </div>
        </div>
    </div>
</div>

        </div>
        <div class="footer">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <div class="footer-inner">
          <h2 class="footer-title">Digital PRISM – Therapeutic Intelligence</h2>
          <ul>
            
            
            <li class="">
              <a href="/">Home</a>
            </li>
            
            <li class="">
              <a href="/contact/">Contact</a>
            </li>
            
            <li class="">
              <a href="/impressum/">Impressum</a>
            </li>
            
          </ul>
        </div>
      </div>
    </div>
  </div>
</div>
 <div class="sub-footer">
  <div class="container">
    <div class="row">
      <div class="col-12">
        <div class="sub-footer-inner">
          
            <div class="social">
  
    <a href="mailto:markus.dahlem@dahlem.ch " target="blank"><img src="/images/social/email.svg" title="Email" alt="Email" /></a>
  
</div>

          
          
          <div class="copyright">Based in Jekyll theme by <a class="zerostatic" href="https://www.zerostatic.io">www.zerostatic.io</a></div>
          
        </div>
      </div>
    </div>
  </div>
</div>
        <script
            type="text/javascript"
            src="/assets/js/scripts.js"
        ></script>
        
    </body>
</html>
